May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Ocular Toxicity of Intravitreous Adalimumab (Humira) in the Rabbit
Author Affiliations & Notes
  • H. M. Kwong, Jr.
    Department of Ophthalmology, Tulane School of Medicine, New Orleans, Louisiana
  • R. P. A. Manzano
    Department of Ophthalmology, Tulane School of Medicine, New Orleans, Louisiana
    Department of Ophthalmology, University of São Paulo, São Paulo, Brazil
  • G. A. Peyman
    Department of Ophthalmology, Tulane School of Medicine, New Orleans, Louisiana
    Department of Ophthalmology, University of Arizona, Tucson, Arizona
  • P. E. Carvounis
    Department of Ophthalmology, Baylor College of Medicine, Houston, Texas
  • P. Chévez-Barrios
    Department of Pathology, The Methodist Hospital, Houston, Texas
  • M. Kivilcim
    Department of Ophthalmology, Tulane School of Medicine, New Orleans, Louisiana
    Department of Ophthalmology, University of Arizona, Tucson, Arizona
  • P. Khan
    Department of Ophthalmology, Tulane School of Medicine, New Orleans, Louisiana
  • Footnotes
    Commercial Relationships H.M. Kwong, None; R.P.A. Manzano, None; G.A. Peyman, None; P.E. Carvounis, None; P. Chévez-Barrios, None; M. Kivilcim, None; P. Khan, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 79. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. M. Kwong, Jr., R. P. A. Manzano, G. A. Peyman, P. E. Carvounis, P. Chévez-Barrios, M. Kivilcim, P. Khan; Ocular Toxicity of Intravitreous Adalimumab (Humira) in the Rabbit. Invest. Ophthalmol. Vis. Sci. 2007;48(13):79.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the ocular toxicity of escalating doses of intravitreous adalimumab (Humira) in the rabbit eye.

Methods:: Twelve New Zealand albino rabbits received unilateral intravitreous injections of 0.1ml of adalimumab 250 mcg (3 eyes), 500mcg (3 eyes), 1000mcg (3 eyes) or 0.1ml balanced salt solution (BSS, 3 eyes). Slit lamp biomicroscopy, fundoscopy were carried out at baseline, day 1, 7 and 14 following intravitreous injection where electroretinography (ERG) was carried out at baseline and day 14. Animals were euthanized on day 14 and histopathological examination of the eyes was performed.

Results:: Slit lamp biomicroscopy and fundoscopy were normal in eyes having received BSS, 250mcg or 500 mcg adalimumab, however, inflammation was present in 2/3 eyes having received 1000mcg adalimumab. Similarly, comparison of scotopic and photopic ERG light at baseline and day 14 demonstrated no changes in eyes receiving BSS, 250mcg or 500mcg adalimumab but 2 of 3 eyes having received 1000mcg adalimumab showed a greater than 30% reduction in a- and b- wave. Finally, histopathology demonstrated no differences between eyes receiving BSS, 250mcg or 500mcg of adalimumab, but 2 of 3 eyes injected with 1000mcg demonstrated inflammatory cell infiltration of the vitreous and anterior chamber with 1 of these eyes demonstrating retinal necrosis.

Conclusions:: Escalating doses of intravitreous adalimumab had no associated ocular toxicity up to 500mcg. Administration of 1000mcg in 0.1ml was associated with an inflammatory reaction and retinal necrosis.

Keywords: drug toxicity/drug effects • electroretinography: non-clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×